IPO4U — Indian IPO GMP & Intelligence Platform
Quick Jump
Use ↑ ↓ to navigate · Enter to openEsc to close
Open IPOs
MainboardNSE/BSEUpcoming6 min read11 sections

Integris Medtech IPO Review

Independent research breakdown covering business fundamentals, financial trajectory, valuation context, and key risk factors.

Full IPO Details

Issue Size

TBA

Price Band

TBA

Face value ₹1

Issue Dates

27 Nov 2026 - 1 Dec 2026

2026

Lot Size

TBA

Mainboard

Min. Investment

TBA

Pending price band

Latest GMP

Not Active

Unofficial indicator

Executive Summary

Subscription Verdict & Summary

Await RHP & Price Band

Integris Medtech presents a fundamentally sound, diversified MedTech platform with global manufacturing, proprietary cardiovascular brands, and a turnaround to profitability in FY25. Strengths include revenue scale (~₹1,960 Cr), improving margins, large SKU portfolio, and a significantly deleveraged balance sheet post fresh equity infusion.

However, the anomalous Q1 FY26 profit surge, opacity around the ₹600 Cr fresh issue deployment (general corporate purposes), foreign promoter structure, and intense global competition warrant caution. Valuation assessment is impossible without the price band.

Retail investors with moderate risk appetite seeking exposure to the MedTech manufacturing export story may track the issue, but should await the RHP for earnings quality reconciliation, peer valuation multiples, and detailed object-wise fund utilisation.

Balanced Assessment · Bull Case vs. Watchouts

Key Strengths & Risk Factors

Key Investment Strengths

6 pts
  • 01.Diversified product portfolio of 22,000+ SKUs across 200+ brands reduces single-product dependency.
  • 02.Global manufacturing footprint (India, Germany, Netherlands) enables supply chain resilience and regulatory proximity for EU (MDR) and Indian markets.
  • 03.Established proprietary cardiovascular brands (Chrome, Protégé) in Europe provide pricing power.
  • 04.Broad customer base of 9,500+ labs and 2,000+ hospitals across 65+ countries mitigates concentration risk.
  • 05.Clinical trial infrastructure (15,000+ patients, 100+ sites) supports innovation pipeline.
  • 06.Recent deleveraging (borrowings down 54% QoQ) and strong net worth (₹3,890 Cr) post equity infusion strengthen the balance sheet ahead of listing.

Key Risk Factors

7 pts
  • 01.The Q1 FY26 PAT spike (₹267.57 Cr vs FY25 ₹70.68 Cr) raises sustainability questions; investors must verify core earnings quality in RHP.
  • 02.High reliance on European cardiovascular segment exposes business to EU MDR regulatory compliance costs and currency fluctuations.
  • 03.Foreign promoter holding structure (Singapore entities) may lead to governance complexities and potential related-party transactions.
  • 04.No OFS means promoters aren't monetising, but also signals no immediate liquidity event for them.
  • 05.General corporate purposes as use of proceeds lacks specific project visibility.
  • 06.Integration risk across three manufacturing geographies and 200+ brands requires management bandwidth.
  • 07.Competition from well-capitalised MNCs in both cardio and diagnostics segments persists.
01.

Company Overview

Integris Medtech Ltd, incorporated in 2008, is a diversified global MedTech company operating across cardiovascular devices, clinical diagnostics, and scientific laboratory solutions. The company follows an integrated model encompassing development, manufacturing, and commercialisation.

It maintains a manufacturing footprint in India, Germany, and the Netherlands, supplying products to over 65 countries. Its customer network includes 9,500+ laboratories and 2,000+ hospitals and cathlabs.

The business is split between an Asia-focused laboratory/hospital segment and a Europe-centric cardiovascular segment with proprietary brands such as Chrome and Protégé. As of June 2025, the workforce stood at 1,879 employees supporting global operations and clinical trial activities across 100+ sites.

02.

Business Model

The revenue model relies on selling a vast portfolio of 22,000+ SKUs across 200+ brands to both public and private healthcare institutions. Revenue streams are geographically diversified with strong presence in India, Europe, and Southeast Asia, alongside Rest of World markets.

The company operates two core divisions: one serving laboratories and hospitals in Asia and another focusing on cardiovascular products in Europe. Customer concentration risk appears mitigated by a large base of 11,500+ institutional accounts.

However, dependency on proprietary cardiovascular brands in Europe and regulatory approvals across multiple jurisdictions creates operational execution dependencies.

03.

Industry Context

The global medical devices and diagnostics industry is driven by aging populations, rising chronic disease prevalence, and increasing healthcare expenditure in emerging markets. India's MedTech sector benefits from government initiatives like PLI schemes and Ayushman Bharat.

The cardiovascular segment sees innovation in minimally invasive procedures, while diagnostics demand grows with preventive healthcare trends. Competitive pressures are intense from large global MNCs (Medtronic, Abbott, Siemens) and domestic players (Poly Medicure, Meril Life).

Regulatory hurdles (MDR in EU, CDSCO in India) and pricing pressure in public procurement pose challenges. Integris's multi-geography manufacturing and broad SKU portfolio position it as a mid-sized diversified player.

04.

Issue Details & Capital Structure

The IPO comprises a Fresh Issue of ₹600 crore with no Offer for Sale (OFS) component indicated, meaning all proceeds flow to the company for general corporate purposes and business expansion. The price band is yet to be announced.

The issue is scheduled to open on November 27, 2026, and close on December 1, 2026, on the Mainboard of NSE and BSE. Lot size and minimum retail investment will be determined post price band finalisation.

Absence of OFS signals promoter confidence and ensures capital directly fuels growth and debt reduction, as suggested by the sharp borrowing decline between March and June 2025.

05.

Bidding Schedule & Lot Sizes

The IPO bidding window is scheduled from November 27, 2026, to December 1, 2026. Basis of allotment is expected around December 4, 2026, with refunds/unblocking by December 5, 2026, and demat credit by December 8, 2026.

Tentative listing date is December 9, 2026, on NSE and BSE. Since the price band is unannounced, the minimum retail lot investment (typically ₹14,000-₹15,000) cannot be calculated yet.

Retail investors should monitor the RHP for final price band, lot size, and anchor investor allocation details. The 3-day bidding window is standard for mainboard issues.

06.

Financial Performance & Margins

Financials show consistent revenue growth: ₹1,369.66 Cr (FY23) → ₹1,582.26 Cr (FY24) → ₹1,959.58 Cr (FY25). EBITDA improved from ₹168.82 Cr (FY23) to ₹309.40 Cr (FY25), with margins expanding from 12.3% to 15.8%.

PAT turned positive in FY25 at ₹70.68 Cr after losses of ₹40.54 Cr (FY23) and ₹4.88 Cr (FY24). The Q1 FY26 (Jun'25) PAT of ₹267.57 Cr is anomalously high versus the full prior year, warranting scrutiny for one-time items.

Net Worth surged to ₹3,889.99 Cr (Jun'25) from ₹2,752.52 Cr (Mar'25), while borrowings fell sharply to ₹793.42 Cr from ₹1,729.46 Cr, indicating deleveraging via fresh equity.

Company Financials (Restated Consolidated)Figures in Amount in ₹ Crore
Period Ended30 Jun 202531 Mar 202531 Mar 202431 Mar 2023
Assets4,019.623,641.342,989.202,553.87
Total Income508.931,959.581,582.261,369.66
Profit After Tax267.5770.68-4.88-40.54
EBITDA78.73309.40190.45168.82
NET Worth3,889.992,752.522,681.022,629.52
Reserves and Surplus2,299.841,150.741,135.711,073.12
Total Borrowing793.421,729.46813.10556.54
07.

Peer Valuation & Industry Comparison

Key listed peers in the diversified MedTech/diagnostics space include Poly Medicure, Meril Life Sciences (recently listed), Trivitron Healthcare (unlisted), and global giants like Siemens Healthineers (listed via parent). Integris differentiates with a unique dual focus on cardiovascular devices (proprietary EU brands) and laboratory diagnostics, alongside multi-country manufacturing.

Revenue scale (~₹1,960 Cr FY25) places it in the mid-tier. Poly Medicure (FY24 Rev ~₹1,100 Cr) is smaller but pure-play; Meril is larger (~₹3,000 Cr+).

Integris's EBITDA margin (~16%) is competitive. However, lack of OFS and high promoter holding via foreign entities contrasts with typical Indian promoter-led structures.

Valuation benchmarks will depend on the undisclosed price band.

08.

Promoters & Corporate Governance

Promoters include Singapore-based entities Evercure Holdings Pte. Ltd. and Medicore Holdings Pte.

Ltd., alongside individual promoters Gurmit Singh Chugh and Punita Sharma. The foreign promoter structure suggests potential private equity or strategic investor backing prior to listing.

The leadership team manages complex multi-jurisdictional operations across three manufacturing sites and 65+ markets. Corporate governance will be tested post-listing given the cross-border holding structure; investors should scrutinise related-party transactions and board independence in the RHP.

The sharp increase in Net Worth and Reserves by June 2025 indicates recent equity infusion, likely linked to pre-IPO rounds involving these entities.

This review is published strictly for informational and research purposes and does not constitute SEBI-registered investment advice. Always verify issue terms against the official Red Herring Prospectus (RHP) and consult a certified financial advisor before applying.